Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4513902 | 1.00 | RIPK1 (0.31) | RIPK1MEN1ALDH1A1TSHRKMT2A | |
| SCHEMBL3403084 | 1.00 | RIPK1 (0.31) | RIPK1MEN1ALDH1A1TSHRKMT2A | |
| SCHEMBL3405196 | 1.00 | RIPK1 (0.31) | RIPK1MEN1ALDH1A1TSHRKMT2A | |
| SCHEMBL2586430 | 0.87 | RIPK1 (0.34) | RIPK1MEN1ALDH1A1TSHRKMT2A | |
| SCHEMBL3627713 | 0.83 | P2RX7 (0.36) | MEN1ALDH1A1TSHRKMT2AP2RX7 | |
| SCHEMBL2577904 | 0.83 | P2RX7 (0.33) | MEN1ALDH1A1TSHRKMT2AP2RX7 | |
| SCHEMBL5126234 | 0.83 | P2RX7 (0.36) | MEN1ALDH1A1TSHRKMT2AP2RX7 | |
| SCHEMBL2579829 | 0.83 | P2RX7 (0.36) | MEN1ALDH1A1TSHRKMT2AP2RX7 | |
| SCHEMBL3623316 | 0.83 | P2RX7 (0.36) | MEN1ALDH1A1TSHRKMT2AP2RX7 | |
| SCHEMBL8136568 | 0.82 | TSHR (0.44) | RIPK1MEN1ALDH1A1TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100280243-A1 | PROCESS FOR PRODUCTION OF 4- (SUBSTITUTED PHENYL) HEXAHYDROPYRIDO [2,1-C] [1,4] OXAZIN-6-ONE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-11-04 | — | — | US | claimed |
| EP-2226325-A1 | PROCESS FOR PRODUCTION OF 4-(SUBSTITUTED PHENYL)HEXAHYDROPYRIDOÝ2,1-C¨Ý1,4¨OXAZIN-6-ONE | Eisai R&D Management Co., Ltd. (JP) | 2010-09-08 | — | — | EP | claimed |
| EP-1953158-B1 | BICYCLIC CINNAMIDE COMPOUND | EISAI R&D MAN CO LTD (JP) | 2012-09-12 | — | — | EP | disclosed |
| US-8048878-B2 | Two cyclic cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-11-01 | — | — | US | disclosed |
| US-20100280243-A1 | PROCESS FOR PRODUCTION OF 4- (SUBSTITUTED PHENYL) HEXAHYDROPYRIDO [2,1-C] [1,4] OXAZIN-6-ONE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-11-04 | — | — | US | disclosed |
| US-20100280243-A1 | PROCESS FOR PRODUCTION OF 4- (SUBSTITUTED PHENYL) HEXAHYDROPYRIDO [2,1-C] [1,4] OXAZIN-6-ONE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-11-04 | — | — | US | disclosed |
| US-20100280243-A1 | PROCESS FOR PRODUCTION OF 4- (SUBSTITUTED PHENYL) HEXAHYDROPYRIDO [2,1-C] [1,4] OXAZIN-6-ONE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-11-04 | — | — | US | disclosed |
| EP-2226325-A1 | PROCESS FOR PRODUCTION OF 4-(SUBSTITUTED PHENYL)HEXAHYDROPYRIDOÝ2,1-C¨Ý1,4¨OXAZIN-6-ONE | Eisai R&D Management Co., Ltd. (JP) | 2010-09-08 | — | — | EP | disclosed |
| US-7737141-B2 | such as -{4-{1-[(S)-1-(4-fluorophenyl)ethyl]-2-oxopiperidin-(3E)-ylidenemethyl}-2-methoxyphenyl}-5-methyl-1-(phosphonooxymethyl)-3H-imidazol-1-ium trifluoroacetate, which inhibit the synthesis of amyloid precursor proteins; treatment of Alzheimer's disease, Down syndrome or amyloidosis | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-06-15 | — | — | US | disclosed |
| US-20090181945-A1 | TWO CYCLIC CINNAMIDE COMPOUND | KIMURA TEIJI | 2009-07-16 | — | — | US | disclosed |
| WO-2009081959-A1 | PROCESS FOR PRODUCTION OF 4-(SUBSTITUTED PHENYL)HEXAHYDROPYRIDO[2,1-C][1,4]OXAZIN-6-ONE | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-07-02 | — | — | WO | disclosed |
| EP-2048143-A1 | PRODRUG OF CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2009-04-15 | — | — | EP | disclosed |
| US-20090048213-A1 | Prodrug of cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. | 2009-02-19 | — | — | US | disclosed |
| EP-1953158-A1 | BICYCLIC CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2008-08-06 | — | — | EP | disclosed |
| US-20070117839-A1 | Two cyclic cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280243-A1 | PROCESS FOR PRODUCTION OF 4- (SUBSTITUTED PHENYL) HEXAHYDROPYRIDO [2,1-C] [1,4] OXAZIN-6-ONE | PSEN1, APP, BACE1 | RIPK1 3854/4885MEN1 1593/4885ALDH1A1 277/4885 |
| US-20090181945-A1 | TWO CYCLIC CINNAMIDE COMPOUND | APP, BACE1, PSEN1 | RIPK1 4491/4885MEN1 184/4885ALDH1A1 869/4885 |
| US-20090048213-A1 | Prodrug of cinnamide compound | BTK, CNKSR1, AKT1 | RIPK1 2821/4885MEN1 597/4885ALDH1A1 674/4885 |
| US-20070117839-A1 | Two cyclic cinnamide compound | APP, BACE1, PSEN1 | RIPK1 4491/4885MEN1 184/4885ALDH1A1 869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.